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Abstract Objective To develop an evidence-based
checklist to identify potential drug related problems (PDRP)
in patients with type 2 diabetes. Setting The evidence based
checklist was applied to records of ambulatory type 2 dia-
betes patients in New South Wales, Australia. Method After
comprehensive review of the literature, relevant medication
groups and potential drug related problems in type 2 dia-
betes were identiﬁed. All the relevant information was then
structured in the form of a checklist. To test the utility of the
evidence-based checklist a cross-sectional retrospective
study was conducted. The PDRP checklist was applied to
the data of 148 patients with established type 2 diabetes and
poor glycaemic control. The range and extent of DRPs in
this population were identiﬁed, which were categorized
using the PCNE classiﬁcation. In addition, the relationship
between the total as well as each category of DRPs and
several of the patients’ clinical parameters was investigated.
Main outcome measure: Number and category of DRPs per
patient. Results The PDRP checklist was successfully
developed and consisted of six main sections. 682 potential
DRPs were identiﬁed using the checklist, an average of 4.6
(SD = 1.7) per patient. Metabolic and blood pressure con-
trol in the study subjects was generally poor: with a mean
HbA1c of 8.7% (SD = 1.5) and mean blood pressure of
139.8 mmHg (SD = 18.1)/81.7 mmHg (SD = 11.1). The
majority of DRPs was recorded in the categories ‘therapy
failure’ (n = 264) and ‘drug choice problem’ (n = 206).
Potentially non-adherent patients had a signiﬁcantly higher
HbA1c than patients who adhered to therapy (HbA1c of
9.4% vs. 8.5%; P = 0.01). Conclusion This is the ﬁrst tool
developed speciﬁcally to detect potential DRPs in patients
with type 2 diabetes. It was used to identify DRPs in a
sampleoftype2diabetespatientsanddemonstratedthehigh
prevalence of DRPs per patient. The checklist may assist
pharmacists and other health care professionals to system-
atically identify issues in therapy and management of their
type 2 diabetes patients and enable earlier intervention to
improve metabolic control.
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Impact of ﬁndings on practice
• An evidence-based checklist can be used speciﬁcally in
patients with type 2 diabetes, to assist pharmacists and
other healthcare professionals in systematically identi-
fying DRPs.
• There is a high prevalence of DRPs in the population of
patientswithtype2diabetesandpoorglycaemiccontrol.
• The most important DRPs in type 2 diabetes patients
in New South Wales seem to be therapy failure and drug
choice problems.
Introduction
Type 2 diabetes is a chronic metabolic disorder character-
ised by both defects in insulin secretion and/or tissue
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tance and forms part of a cluster of cardiovascular risk
factors seen in a high proportion of patients with type 2
diabetes. It is known as the metabolic syndrome and also
includes central obesity, hypertension and/or dyslipidaemia.
Evidence suggests that a targeted, intensiﬁed, multifactorial
intervention which includes lifestyle modiﬁcations and
multiple pharmacotherapy is required to reduce or prevent
macrovascular and microvascular complications [1, 2].
The optimal use of medications therefore plays a key role
in achieving treatment targets for glucose, blood pressure
and lipids. The efﬁcacy of a medication regimen, however,
may be limited by a range of drug related problems (DRPs)
including adverse drug reactions, interactions, contra-indi-
cations and non-adherence [3]. Since patients with type 2
diabetes generally use multiple medications, DRPs are
likely to occur in this population and these can negatively
inﬂuence diabetes control. Research has shown that a sub-
stantial proportion of DRPs that exist within the health care
system are related to patients with diabetes [4]. Neverthe-
less, there is currently no speciﬁc tool available that can be
used by pharmacists or other healthcare professionals to
help detect DRPs in patients with type 2 diabetes.
Aim
Our aim was to develop an evidence-based PDRP (poten-
tial drug related problems) checklist that may be used to
review a patient’s clinical status and medication regimen to
identify potential DRPs in type 2 diabetes.
Method
Development of the checklist
The development of the PDRP checklist followed a sys-
tematic process which is outlined in Fig. 1. Initially, a
MEDLINE search of English-language articles published
between 1997 and 2007 with the terms ‘type 2 diabetes
mellitus’ and ‘drug therapy’ was conducted to identify
published literature on the subject. The available literature
was comprehensively reviewed to provide up to date
information on the pharmacological management of type 2
diabetes and the risk management of its related complica-
tions. In addition, current standards in the therapeutic
management of type 2 diabetes were obtained by reviewing
several recently published guidelines [5–8]. According to
all guidelines, the current recommended targets for type 2
diabetes for glycaemic control and cardiovascular risk
reduction are HbA1c B7%, blood pressure\130/80 mmHg
(125/75 mmHg in case of proteinuria [1 g/day). With
respect to lipids, Australian guidelines recommend total
cholesterol \4 mmol/l; LDL-C \2.0 mmol/l; HDL-C
[1.0 mmol/l; triglycerides\1.5 mmol/l [7]. In the US and
Europe the recommended levels for lipids are expressed in
mg/dl (LDL-C \100 mg/dL; HDL-C [40 mg/dl; triglyc-
erides\150 mg/dl) [5].
Based on this, the therapeutic targets and the drug
groups to be included in the PDRP checklist were selected
(displayed in Table 1) and the potential DRPs related to
each group were identiﬁed. All the relevant information
was then structured in the form of a checklist. To enable
easy application in clinical practice, the checklist must be
relatively short and concise. Therefore, very rarely used
agents (e.g. bile acid binding resins and nicotinic acid for
the treatment of dyslipidaemia), were excluded. In addi-
tion, only the most common and/or most severe adverse
effects, contra-indications and signiﬁcant interactions were
listed [9]. (i.e., drug interactions with a signiﬁcance rating
of 1 or 2 in the Drug Interaction Facts software) [10].
Dosage information for each agent was derived from the
Australian Medicines Handbook [9]. After the checklist
had initially been developed by the authors, it was exten-
sively reviewed by a panel of experts and corrected here-
after (see Acknowledgements).
Using the PDRP checklist
In the literature, there are several systems available for the
classiﬁcation of DRPs [11]. The characteristics of each
2. Identification of medication groups to be included in 
the tool 
3. Identification of potential DRPs related to these 
medication groups based on literature references 
4. Structuring of all the relevant information in the form 
of a checklist 
5. Categorization of the DRPs into the categories of the 
PCNE classification
6. Using the tool retrospectively in a population of 148 
patients with type 2 diabetes
1. Literature review on the pharmacotherapy of type 2 
diabetes and the risk management of its complications
Fig. 1 The development of the PDRP checklist
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classifying the outcomes of the PDRP checklist. The PCNE
classiﬁcation proved to be the most appropriate one to
apply in this study [12]. It is based on a clear deﬁnition, has
a hierarchical problem classiﬁcation and its validation has
been published [11]. The outcomes of the checklist
appeared to be easily categorized into one of the six pri-
mary domains of this classiﬁcation: adverse reactions, drug
choice problems, dosing problems, drug use problems,
interactions and others. In this study, the primary domain
called ‘others’ was renamed to ‘therapy failure’ because
that is the only type of DRP in this domain that was
investigated in this study.
A cross-sectional retrospective study design was used.
Study subjects were patients from New South Wales,
Australia who participated in the Pharmacy Diabetes Care
Program in 2004 [13]. These were all patients with estab-
lished type 2 diabetes and poor glycaemic control (HbA1c
C7.0%). Full patient medication records and other data
collected in the study, including BMI, HbA1c, systolic and
diastolic blood pressure, lipid proﬁle and medication
adherence were available.. Adherence was assessed using
the Brief Medication Questionnaire (BMQ), a validated
self-report tool that is used to indicate potential non-
adherence [13, 14]. No further data from the patients’
perspective were available. The PDRP checklist was used
to review each patient’s data to determine the prevalence of
identiﬁed DRPs.
Data analysis
For each type of DRP identiﬁed in the review process, the
cumulative frequencies and, if relevant, the nature of the
problem was reported. All the DRPs were categorized
according to their primary domain in the PCNE classiﬁ-
cation. Next, the relationship between the total number and
category of DRPs and several clinical parameters was
investigated using either the Spearman’s rank correlation
coefﬁcients (for continuous or ordinal variables) or the
independent-samples Student’s t-tests for comparing means
of two groups. The DRPs in the ‘therapy failure’ category
were not included in this analysis, since the occurrence of a
DRP in this category is logically related to poor control of
blood glucose levels, blood pressure and/or lipid levels. All
the statistical analyses were carried out using SPSS for
Windows (version 15.0; SPSS Inc, Chicago, IL, USA).
Results
The PDRP checklist
The checklist (see Appendix) consists of six main sections:
lifestyle management, glycaemic control, blood pressure
control, lipid control, platelet control and medication
adherence. Whilst the main focus of the checklist is on the
detection of potential DRPs in the patient’s current medi-
cations, including missing therapy and the appropriateness
of the prescribed agents, lifestyle management issues are
also relevant in the overall management of type 2 diabetes
and were therefore included.
Sample description
A total of 148 patients with established type 2 diabetes
were included in the study. The demographics and clinical
parameters of these study subjects are displayed in Table 2.
In total, the study subjects were using 599 medications of
the four main groups that were included in the checklist. Of
these 599 medications, 258 (43.1%) were anti-diabetics,
200 (33.4%) were anti-hypertensives, 80 (13.4%) were
lipid lowering drugs and 61 (10.2%) were anti-platelet
agents (Table 3).
Distribution of drug related problems
A total of 682 DRPs were identiﬁed using the PDRP
checklist. This represents an average of 4.6 (SD = 1.7)
DRPs per patient. The distribution of the recorded DRPs is
presented in Table 4.
Table 1 Drug groups included in the protocol
Anti-diabetics
Sulphonylureas
Metformin
Thiazolidinediones
Acarbose
Repaglinide
Insulin
Anti-hypertensives
Thiazide diuretics
b-Blockers
ACE inhibitors
Angiotensin II antagonists
Calcium channel blockers
Selective a-blockers
Lipid lowering drugs
Statins
Fibrates
Anti-platelet drugs
Aspirin
Clopidogrel
Dipyridamole
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43 patients (29.1%) reported having experienced at least
one episode of hypoglycaemia of any kind in the 1 month
period prior to enrollment in the study. All these patients
were using a sulphonylurea or insulin, therefore this was
considered a potential adverse effect of their drug therapy.
Drug choice problem
This category of DRP was recorded 206 times, resulting in
an average of 1.4 drug choice problem per patient. By far
the most recorded drug choice problem (n = 182) was that
of missing therapy despite a clear indication being present.
A total of 90 patients (60.8%) were not receiving anti-
platelet therapy although they were at increased cardio-
vascular risk, 71 patients (48.0%) were missing lipid
lowering therapy, 20 patients (13.5%) were missing anti-
hypertensive therapy and 1 patient (0.7%) was not pre-
scribed any blood glucose lowering therapy at the point of
data collection.
Also, drugs that were not the most appropriate treatment
option were prescribed in 19 cases. These were all related
to the use of a non-preferred agent as monotherapy for the
treatment of hypertension: diltiazem or verapamil was
recorded 12 times, a non-selective b-blocker was recorded
6 times and 1 patient only used a selective a-antagonist to
treat high blood pressure.
Dosing problem
In total, a dosing problem was recorded 40 times. Under-
utilization of a drug was recorded when the prescribed dose
was below the recommended range or when the dosing
regimen was inappropriately infrequent. This was seen 13
times, with the most prevalent being aspirin (n = 4) or
ACE inhibitors (n = 4). Overutilization was recorded 27
times. In 15 of these cases, sulphonylureas were respon-
sible for this type of DRP. ACE inhibitors (n = 4) and
metformin (n = 3) were the next most frequently overuti-
lized drugs.
Drug use problem
Potential non-adherence was categorized as a drug use
problem and occurred in 17.6% (n = 26) of the study
subjects.
Table 2 Demographics and clinical parameters of study subjects
Demographics (n = 148)
Male (%) 50.7%
Age (in years; mean ± SD) 61.4 ± 11.8
Duration of type 2 diabetes (in years; mean ± SD) 9.0 ± 7.5
Clinical parameters n Mean ± SD
HbA1c (%) 146 8.7 ± 1.5
BMI (kg/m
2) 140 31.9 ± 6.9
Systolic blood pressure (mmHg) 122 139.8 ± 18.1
Diastolic blood pressure (mmHg) 122 81.7 ± 11.1
Total cholesterol (mmol/l) 146 4.8 ± 1.0
HDL cholesterol (mmol/l) 130 1.3 ± 0.7
Triglycerides (mmol/l) 145 2.3 ± 1.3
10 year risk of cardiovascular events
a (%) 116 16.4 ± 8.8
a Estimated with the Framingham risk calculator [26]
Table 3 Use of medications in the study subjects (n = 148)
Category n Percentage of patients
Anti-diabetics 258
Sulphonylureas 92 63
Metformin 117 79
Thiazolidinediones 9 6
Acarbose 6 4
Insulin 34 23
Proportion of patients using
1 anti-diabetic 55 37
2 anti-diabetics 74 50
3 anti-diabetics 18 12
Anti-hypertensives 200
Thiazide diuretics 38 26
b-Blockers 26 18
ACE inhibitors 51 35
Angiotensin II antagonists 45 30
Calcium channel blockers 39 26
Selective a-blockers 1 1
Proportion of patients using
1 anti-hypertensive 53 36
2 anti-hypertensives 40 27
3 anti-hypertensives 13 9
4 anti-hypertensives 3 2
Lipid lowering drugs 80
Statins 75 51
Fibrates 5 3
Proportion of patients using
1 lipid lowering drug 78 53
2 lipid lowering drugs 1 1
Anti-platelet drugs 61
Aspirin 48 32
Clopidogrel 10 7
Dipyridamole 3 2
Total 599
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A total of 103 potential interactions were identiﬁed with
the use of the checklist. The most recorded type of
potential interaction was the combination of an ACE
inhibitor with either a sulphonylurea (n = 32) or insulin
(n = 14). The so-called ‘triple whammy’, deﬁned as the
use of a thiazide diuretic and an ACE inhibitor or angio-
tensin II antagonist in combination with an NSAID, was
observed 15 times [15]. Other repeatedly reported potential
interactions were the concomitant use of low-dose aspirin
and another NSAID (n = 7); atorvastatin or simvastatin
and a macrolide antibiotic (n = 6); a sulphonylurea and an
antimalarial drug (n = 6); and an ACE inhibitor as well as
an angiotensin II antagonist (n = 6).
Therapy failure
This was the largest category of DRPs (n = 264),
accounting for 38.7% of all problems. Therapy failure was
assumed to be present when blood glucose levels, blood
pressure or lipid levels weren’t controlled adequately
despite receiving drug therapy to treat these metabolic
disorders. The underlying causes of the DRPs in this cat-
egory are unknown; potential causes are ineffectiveness of
medications (e.g. secondary failure of sulphonylureas),
missing therapy (e.g. patients requiring more than one
antihypertensive to control their blood pressure), incorrect
administration of drugs and undetected non-adherence.
Therefore, not reaching therapeutic targets while receiving
drug therapy was recorded as a separate DRP in this cat-
egory. Blood glucose levels were above recommended
levels in 133 patients (89.9%), blood pressure was elevated
in 69 patients (46.6%) and lipid levels failed to reach the
treatment goals in 62 patients (41.9%).
To investigate whether there was a relationship between
the prevalence of DRPs and the therapeutic status of the
patient; Spearman’s correlation coefﬁcients were calcu-
lated between the number of total DRPs (minus the ‘ther-
apy failure’ category) and several clinical parameters. A
signiﬁcant correlation was observed between systolic blood
pressure and the total number of DRPs minus ‘therapy
failure’ (Spearman’s correlatio n = 0.19; P = 0.028).
Potentially non-adherent patients had a signiﬁcantly higher
HbA1c than the other patients (HbA1c of 9.4 vs. 8.5; 95%
CI: -1.50 to -0.20).
Discussion
Inthisstudy,anevidence-basedchecklistforthedetectionof
DRPs in type 2 diabetes has successfully been developed.
The checklist was used to identify DRPs in a population of
patients with type 2 diabetes. A total of 682 DRPs were
detected, which were classiﬁed in six different categories.
The high average of 4.6 DRPs (SD = 1.7) per patient
showed that the early identiﬁcation and resolution of DRPs
is important in the therapeutic management of patients with
type 2 diabetes. An earlier study found a comparable
average of 4.1 DRPs per patient with type 2 diabetes, albeit
using a different method of detecting (by qualitative
interviews) and classifying DRPs [16]. Collectively, these
ﬁndings demonstrated that the prevalence of DRPs in these
patients is relatively high. This can partly be explained by
the fact that patients with type 2 diabetes generally use
many medications, but it also emphasizes the need for
adequate medication management in these patients.
One of the major issues identiﬁed by the PDRP checklist
was the large proportion of patients who were missing
therapy for clear indication. This was especially the case
for anti-platelet therapy, Approximately 60% of all the
patients were not taking aspirin in spite of being at
increased cardiovascular risk. Also, nearly half of all the
patients were not receiving any lipid lowering drugs
although lipid levels were not adequately controlled in
these patients. This is a concern, especially since the ben-
eﬁts of anti-platelet and lipid lowering therapy in patients
with type 2 diabetes have clearly been established in earlier
large randomized clinical trials [17–19].
A high proportion of patients in this study had poor
glycaemic control, an expected ﬁnding since this was a
selection criterion for entry into study [13]. It suggests,
however, that pharmacotherapy may need to be intensiﬁed
for many poorly controlled patients with type 2 diabetes,
assuming they have been adherent to their diabetes
Table 4 Drug related problems in the study subjects (n = 148)
Type of drug related problem n Percentage
of total
DRPs
1. Adverse reaction 43 6.3
2. Drug choice problem 206 30.2
Inappropriate/not most appropriate drug 19 2.8
Duplication of therapeutic group 1 0.1
Contra-indication 4 0.6
No drug prescribed but clear indication 182 26.7
3. Dosing problem 40 5.9
Drug dose too low or regimen not frequent
enough
13 1.9
Drug dose too high or regimen too frequent 27 4.0
4. Drug use problem 26 3.8
Potential non-adherence 26 3.8
5. Interactions 103 15.1
6. Therapy failure 264 38.7
Total 682 100.0
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need for self monitoring of blood glucose by all type dia-
betes patients on medication therapy.
Blood pressure control among this cohort was also
suboptimal. Nearly half of the patients had an elevated
blood pressure (46.6%) as well as suboptimal lipid control.
(41.9%). Thus, notwithstanding the availability of a wide
range of pharmacotherapy, achieving metabolic control in
type 2 diabetes continues to be a major challenge.
Another notable result was that 16% of all patients in
this study on sulphonylurea therapy were prescribed a dose
that was higher than recommended. The desirability of this
prescribing behaviour is questionable, since it is well
known that the risk of hypoglycaemia is enhanced with
increased dosages of sulphonylureas [20]. Also, approxi-
mately a third of all patients reported having experienced at
least one episode of hypoglycaemia of any kind in the
month before entry into the study. It is not possible, though,
to conclude what proportion of these episodes was directly
induced by sulphonylureas from the retrospective patient
data. Information on other adverse effects was not available
from the patient data, so the number of DRPs collected in
this category may have been underestimated. Also, there
was no information available from the original data on the
patient’s renal and hepatic function; so it was not possible
to detect possible contra-indications related to these
parameters.
Several potential interactions were identiﬁed with the
use of the PDRP checklist. A large proportion (44.7%)
related to the combination of an ACE inhibitor with either
a sulphonylurea or insulin. Although the combination of
these agents is unavoidable in the therapeutic management
of type 2 diabetes for many patients, the increased risk of
hypoglycaemia requires careful monitoring [21, 22]. This
is also true for the potential impairment in renal function
when using the so-called ‘triple whammy’ combination,
which was prescribed in 14.6% of patients. Overall, ACE
inhibitors were involved in 63 of all 103 potential inter-
actions (61.2%), suggesting that patients taking these
agents should be monitored carefully.
An interesting observation was the signiﬁcant difference
in HbA1c between adherent and potentially non-adherent
patients. An earlier observational study demonstrated a
signiﬁcant relationship between adherence to insulin ther-
apy and glycaemic control, but this relationship has not
been established previously for other anti-diabetic medi-
cations [23]. Since 17.6% of the study subjects were
potentially non-adherent, an improvement in medication
adherence is highly likely to contribute to improving gly-
caemic control in type 2 diabetes as has been shown in
earlier studies [24, 25]. It should be noted that the PDRP
checklist does not detect potential non-adherence, but
information on this was available from the patient data. In
these data, potential non-adherence had previously been
assessed by the use of a self-report tool [13]. Considering
the importance of adherence in type 2 diabetes, a tool of
that kind should be integrated in the checklist in the future
to enable full completion and improve convenience.
The total number of DRPs (minus the ‘therapy failure’
category) correlated signiﬁcantly with systolic blood
pressure but not with any other clinical parameters. A
possible explanation for this is that blood glucose and lipid
levels are inﬂuenced to a greater extent by non-medication
related factors, such as environmental and lifestyle aspects,
than is systolic blood pressure.
Certain limitations to this study, however, are due to its
retrospective nature. While the statistical analyses showed
a relationship between the prevalence of DRPs in a patient
and the control of several metabolic parameters, they do
not demonstrate causality. Also, it is unsure whether the
results of this study are representative for all patients with
type 2 diabetes, since nearly all the study subjects had poor
glycaemic control.
Another important factor that should be considered is
that we studied the prevalence of potential DRPs instead of
actual DRPs. Therefore it is unknown whether patients
with more potential DRPs actually had worse clinical
outcomes during follow-up. As a result, the clinical sig-
niﬁcance of the detected DRPs cannot be established. This
is moreover true because no information on the patients’
perspective was included.
The PDRP checklist is the ﬁrst tool developed speciﬁ-
cally to detect potential DRPs in patients with type 2 dia-
betes and was able to identify DRPs from previously
collected patient data. However, the development of an
electronic version will be necessary to allow efﬁcient
future use. The development of this checklist represents an
important ﬁrst step in developing a tool that can be applied
in clinical practice. A broad review on the correctness and
completeness by specialists is needed to further determine
the contents of the checklist. After this, an additional study
on the implementation in practice should be undertaken.
For efﬁcient implementation, collaboration between phar-
macists and physicians is needed; for example in carrying
out the interventions.
The high average of DRPs per patient demonstrates the
importance of the early identiﬁcation and resolution of
DRPs in patients with type 2 diabetes. Therapy failure was
the most frequently recorded DRP, which suggests that to
achieve treatment goals in type 2 diabetes identifying the
cause of therapy failure is a critical step. For example if
non adherence is the issue, behavioural modiﬁcation
strategies may be needed. If failure of therapy is due to beta
cell failure then earlier intensiﬁcation of therapy is likely to
be required [5]. Missing therapy, especially for anti-platelet
and lipid lowering medications, was also common which
Pharm World Sci (2009) 31:580–595 585
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sed in this population.
Conclusion
In conclusion, the wide range of DRPs detected by the
checklist shows that optimal medication management in
type 2 diabetes remains a major challenge in clinical
practice. The use of the PDRP checklist may assist phar-
macists and other health care professionals to systemati-
cally identify issues in therapy and management of their
type 2 diabetes patients and enable earlier intervention to
improve metabolic control. Whether this will translate into
better health outcomes in the longer term, remains to be
proven in the near future.
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Appendix
PDRP checklist: medications in type 2 diabetes
This tool is meant to be used by pharmacists in order to
detect possible drug related problems and/or potential
interventions in patients with type 2 diabetes. It is primarily
focused on a patient’s medications, and includes the most
commonly used agents for the treatment of hyperglyca-
emia, hypertension, dyslipidaemia and hypercoagulability.
Throughout the tool, several footnotes are used. These refer
to the following information:
1 Dietary guidelines for Australian adults are provided by
the NHMRC. These can be accessed through http://www.
nhmrc.gov.au/publications/synopses/_ﬁles/n33.pdf.
2 TheAustralianPhysicalActivityguidelinesrecommend
atleast30minutesofmoderate-intensityphysicalactivityon
most, preferably all, days. These can be accessed through
http://www.ausport.gov.au/fulltext/1999/feddep/physguide.
pdf.
3Renalimpairmentisdeﬁnedbythecreatinineclearance,
which is calculated using the Cockroft-Gault formula:
Creatinine clearance = ((140 - age) * weight * con-
stant)/plasma creatinine
Creatinine clearance in ml/min; age in years; weight in
kilograms; constant = 1.23 for men and 1.04 for women;
plasma creatinine in mg/dl
1Creatinine clearance\10 ml/min = severe renal impair-
ment
2Creatinine clearance 10–25 ml/min = moderate renal
impairment
3Creatinine clearance 25–50 ml/min = mild renal
impairment
4Hepatic impairment is present when transaminase lev-
els are[2.5 times the upper limit of normal
5The advised amounts from the NHMRC guidelines are:
For men: an average of no more than 4 standard drinks a
day, and no more than 28 standard drinks a week; not more
than 6 standard drinks in any one day.
For women: an average of no more than 2 standard
drinks a day, and no more than 14 standard drinks a week;
not more than 4 standard drinks in any one day.
For both men and women, one or two alcohol free days
each week are recommended.
6Heart failure is classiﬁed as:
NYHA Class I: no limitation is experienced in any
activities; there are no symptoms from ordinary activities
NYHA Class II: slight, mild limitation of activity; the
patient is comfortable at rest or with mild exertion
NYHA Class III: marked limitation of any activity; the
patient is comfortable only at rest
NYHA Class IV: any physical activity brings on dis-
comfort and symptoms occur at rest
The Australian Medicines Handbook (AMH Pty Ltd.
July, 2007) was used for the information on dosages.
Drug Interaction Facts on disc v1.0 (1999 Facts and
Comparisons, Medifor Inc, July 2007 edition) was used for
the information on interactions.
Further information was provided by the literature
review.
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1. Is the patient overweight? 
2
2. Is the patient following a healthy diet
1?
3. Is the patient getting regular physical
activity
2? 
4. Is the patient a smoker? 
Glycaemic control
5. What is the patient’s current glycaemic 1c   7.0%
control? 1c > 7.0%
6. Is the patient using: -dose beta2 agonists
Combined oral contraceptives
7. Is the patient using:
Yes: BMI 25.0 kg / m
N o :B M I<2 5 . 0k g/m 2
Yes
No
Yes
No
Yes
No
HbA
HbA
High
Antipsychotics
Glucocorticoids
Immunomodulators
Hormone replacement therapy
Isotrenitoin
Phenytoin
A sulphonylurea
No sulphonylurea
Discuss strategies with the patient to try to lose 
weight
Discuss strategies with the patient to try to modify 
his/her diet
Discuss strategies with the patient to increase the 
amount of physical activity
Discuss strategies with the patient to try to quit 
smoking
Patient’s glycaemic control is good
Patient’s blood glucose is poorly controlled
Check how long these agents have been used and 
how long blood glucose has been elevated; also 
monitor changes in therapy
These medications might increase 
blood glucose concentrations
Ask patient about the monitoring of side effects: 
weight gain and hypoglycaemia 
8. Check if the patient:  as renal impairment
3
4
5
9. Is the daily dose within the recommended 
range?
10. Is the patient also using: 
-dose aspirin
-trimoxazole
11. Is the patient using:
H
Has hepatic impairment
Has irregular eating habits
Consumes more alcohol than advised
Is over 65 years of age
Rifamycins
High
ACE inhibitors
Co
Metformin
No metformin
Patient is at increased risk for 
hypoglycaemia
Glibenclamide: 2.5 – 20 mg in 1 – 2 doses
Glimepiride:  1 – 4 mg in 1 dose
Gliclazide: 40 – 320 mg in 1 – 2 doses
(controlled release): 30 – 120 mg in 1 dose 
Glipizide: 2.5 – 40 mg in 1 – 3 doses
Contact prescriber to adjust dose / frequency  if not 
Closely monitor blood glucose concentrations. 
Sulphonylurea dose may need to be increased
Decrease in sulphonylurea 
metabolism might lead to 
hyperglycaemia
Ask patient about side effects: nausea, vomiting, 
abdominal pain and diarrhea. Check for vitamin 
B12 deficiency
Continue to question 14
Continue to question 11
Use sulphonylureas with caution
Patient is at increased risk for 
hypoglycaemia
Closely monitor blood glucose concentrations. 
Sulphonylurea dose may need to be decreased
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12312. Check if the patient: ilure NYHA Class III or IV
6
3
4
5
13. Is the daily dose within the recommended
range?
14. Is the patient using:
15. Is the patient suffering from:
6
4
16. Is the daily dose within the recommended 
range?
17. Is the patient also using:
Patient is at increased risk of 
lactic acidosis
Contact prescriber: metformin might not be the 
appropriate agent in these conditions
Metformin: 500 – 3000 mg in 1 – 3 doses if not 
Contact prescriber: thiazolidinediones are contra-
indicated in these conditions
Rosiglitazone: 4 – 8 mg in 1 – 2 doses
Pioglitazone: 15 – 45 mg in 1 dose if not 
Increased risk of adverse effects 
such as fluid retention and heart 
failure
Use these combinations with caution 
Closely monitor blood glucose levels  
Thiazolidinedione metabolism 
may be increased
Contact prescriber to adjust dose / frequency 
Ask patient about side effects: weight gain, fluid 
retention, peripheral edema and osteoporosis
Continue to question 18
Contact prescriber to adjust dose / frequency 
18. Is the patient using:
19. Is the patient suffering from:
3
20. Is the daily dose within the recommended
range?
21. Is the patient using:
22. Is the daily dose within the recommended
range?
23. Is the patient also using:
24. Is the patient using:
Has heart fa
Has moderate to severe renal impairment
Has hepatic impairment
Is over 85 years of age
Consumes more alcohol than advised
A thiazolidinedione
No thiazolidinedione
Heart failure NYHA Class III or IV
Hepatic impairment
Gemfibrozil
Insulin
NSAIDs
Rifamycins
Acarbose
No acarbose
Inflammatory bowel disease
Renal impairment
(Partial) intestinal obstruction
Repaglinide
No repaglinide
Gemfibrozil
Cyclosporin
Macrolides (e.g. erythromycin)
Rifamycins
Exenatide
Ask patient about side effects: flatulence, diarrhea 
and abdominal pain 
Continue to question 21
Contact prescriber: acarbose is contra-indicated in 
these conditions
if not 
Ask patient about side effects: hypoglycaemia, 
nausea, diarrhea, vomiting
Repaglinide: 1.5 – 16 mg in 3 doses if not 
Repaglinide metabolism may be 
inhibited
Closely monitor blood glucose concentrations. 
Repaglinide dose may need to be decreased
Repaglinide metabolism may be 
increased
Contact prescriber to adjust dose / frequency  Acarbose:  50 – 600 mg in 1 – 3 doses
Continue to question 24
Contact prescriber to adjust dose / frequency 
Closely monitor blood glucose concentrations. 
Repaglinide dose may need to be increased
Ask patient about side effects: nausea, diarrhea,
vomiting and hypoglycaemia
No exenatide 
Continue to question 27
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12325. Is the daily dose within the recommended
range?
26. Is the patient suffering from:
3
27. Is the patient using:
28. Check if the patient:
3
4
29. Is the patient also using: -dose aspirin
30. When is the patient’s blood 
Contact prescriber: exenatide is contra-indicated 
in this condition
if not 
Use insulin with caution
Patient is at increased risk for 
hypoglycaemia
Patient is at increased risk for 
hypoglycaemia
Contact presciber: add rapid-acting insulin at 
breakfast
Exenatide: 10 – 20 µg in 2 doses Contact prescriber to adjust dose / frequency 
Ask patient about side effects: hypoglycaemia and 
weight gain
Continue to question 31
Closely monitor blood glucose concentrations. 
Insulin dose may need to be adjusted
Contact presciber: reduce bedtime insulin dose 
glucose out of the target range? -lunch hyperglycaemia
The target range is 3.9 – 7.2 mmol / L -dinner hyperglycaemia
-bed hyperglycaemia
Blood pressure control
31. Check if the patient has renal 
impairment
3:
32. What is the patient’s blood pressure?
125/75 mm Hg
33. What is the patient’s blood pressure?
Moderate to severe renal impairment
Insulin
No insulin
Has renal impairment
Has hepatic impairment
Has irregular eating habits
Consumes more alcohol than advised
Is over 65 years of age
High
ACE inhibitors
Daytime hypoglycaemia during fasting
Pre
Pre
Pre
Yes
No
Blood pressure 125/75 mm Hg
Blood pressure >
Blood pressure 130/80 mm Hg
Blood pressure > 130/80 mm Hg
Contact presciber: add intermediate-acting insulin 
at breakfast or rapid-acting insulin at lunch
Contact presciber: add rapid-acting insulin at 
dinner
Continue to question 32
Continue to question 33
Continue to question 35 if the patient is using one 
or more antihypertensive(s), otherwise continue to 
question 61
Patient’s blood pressure is well 
controlled
Continue to question 34
Patient’s blood pressure is 
poorly controlled
Continue to question 34
Patient’s blood pressure is 
poorly controlled
Continue to question 35 if the patient is using one 
or more antihypertensive(s), otherwise continue to 
question 61
Patient’s blood pressure is well 
controlled
poorly controlled
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12334. Is the patient using:
35. Is the patient using: -2 inhibitors)
36. Is the patient using:
37. Is the patient suffering from:
3 
38. Is the daily dose within the recommended
Patient might be in need of an additional 
antihypertensive agent
Missing therapy: Patient is in need of an 
antihypertensive agent. ACE inhibitors and 
angiotensin II antagonists are the preferred agents 
in type 2 diabetes. Continue to question 61
These medications might cause an increase in 
blood pressure: check how long these agents have 
been used and how long blood pressure has been 
elevated; also monitor changes in therapy 
Continue to question 40
Thiazide diuretics are ineffective 
in this condition
Contact prescriber: thiazide diuretics are contra-
indicated in severe renal impairment
Chlorthalidone: 12.5 – 25 mg in 1 dose
Hydrochlorothiazide:  12.5 – 25 mg in 1 dose
Indapamide: 1.25 – 2.5 mg in 1 dose
range?
39. Is the patient also using:
40. Is the patient using: -blocker
-blocker
41. Is the patient suffering from:
42. Which β-blocker is the patient using:
One or more antihypertensive agent(s)
No antihypertensive agents
NSAIDs (including COX
Sibutramine
Corticosteroids
Oral decongestants
MAO inhibitors
Venlafaxine
Cyclosporin
Hormone replacement therapy
Combined oral contraceptives
Haemopoietics
At h i a z i d ed i u r e t i c
No thiazide diuretic
Severe renal impairment
An ACE inhibitor / angiotensin II antagonist
An NSAID (including aspirin)
A β
No β
Bradycardia
Severe asthmatic disease
Atenolol
Metoprolol
Carvedilol
Labetalol
Oxprenolol
Pindolol
Propranolol
43. Is the daily dose within the recommended
range?
Contact prescriber to adjust dose / frequency  if not
When using both of these: increased risk of renal 
impairment; monitor renal function carefully
Ask patient about side effects: nausea, diarrhea, 
bronchospasm, hypotension, cold extremities, 
dizziness, fatigue
Continue to question 45
Contact prescriber: β-blockers are contra-
indicated in these conditions
These agents can mask the symptoms of 
hypoglycaemia to a greater extent than selective 
ones: recommend atenolol or metoprolol instead
Non-selective β-blockers
Atenolol: 25 – 100 mg in 1 dose
Carvedilol: 12.5 – 50 mg in 1 dose
Labetalol: 200 – 800 mg in 2 doses
Metoprolol: 50 – 200 mg in 1 – 2 doses
Oxprenolol: 80 – 320 mg in 2 doses
Pindolol: 10 – 30 mg in 2 – 3 doses
Propranolol: 40 – 320 mg in 2 – 3 doses
Contact prescriber to adjust dose / frequency  if not 
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12344. Is the patient also using:
45. Is the patient using:
46. Is the patient suffering from:
47. Is the daily dose within the recommended
range? 
These agents have additive effects: closely 
monitor blood pressure and cardiac function 
during concomitant use. Bradycardia and / or 
heart block might occur
Closely monitor blood pressure
Antihypertensive effects of       
β-blockers might be decreased
Ask patient about side effects: dry cough, 
headache, dizziness. Check for hyperkalaemia
Continue to question 49
ACE inhibitors may worsen 
renal function
Monitor renal function and use with caution. 
Dosage adjustments might be necessary. Risk of 
hyperkalaemia is also increased: monitor 
potassium levels
Captopril: 25 – 100 mg in 2 doses
Enalapril: 5 – 40 mg in 1 – 2 doses
Fosinopril: 10 – 40 mg in 1 dose
Lisinopril: 5 – 40 mg in 1 dose
Perindopril: 4 – 8 mg in 1 dose
Quinapril: 5 – 40 mg in 1 or 2 doses
Ramipril: 2.5 – 10 mg in 1 or 2 doses
Trandolapril: 1 – 4 mg in 1 dose
Contact prescriber to adjust dose / frequency  if not 
48. Is the patient also using: -sparing diuretics
ntagonists
49.  Is the patient using:
50. Is the patient suffering from:
51. Is the daily dose within the recommended
range?
52. Is the patient also using: -sparing diuretics
Verapamil
Diltiazem
Rifamycins
An ACE inhibitor
No ACE inhibitor
Renal impairment
Potassium
Potassium supplements
Angiotensin II a
Lithium
An angiotensin II antagonist
No angiotensin II antagonist
Renal impairment
Potassium
Potassium supplements
Angiotensin II antagonists
Lithium
Monitor potassium concentrations Increased risk of hyperkalaemia
Monitor serum lithium levels Lithium toxicity might occur
Ask patient about side effect: dizziness. Check for 
hyperkalaemia
Continue to question 53
ACE inhibitors may worsen 
renal function
Monitor renal function and use with caution. Dose 
adjustments might be necessary. Risk of 
hyperkalaemia is also increased: monitor 
potassium levels
Candesartan: 8 – 16 mg in 1 dose
Eprosartan: 400 – 800 mg in 1 dose
Irbesartan: 75 – 300 mg in 1 dose
Losartan: 25 – 200 mg in 1 dose
Telmisartan: 20 – 80 mg in 1 dose
Contact prescriber to adjust dose / frequency  if not 
Monitor potassium concentrations Increased risk of hyperkalaemia
Monitor serum lithium levels Lithium toxicity might occur
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12353. Is the patient using:
54. Which calcium channel blocker is 
the patient using?
55. Is the patient also using:
56. Is the patient suffering from:  – IV 
Ask patient about side effect: flushing, headache, 
ankle edema
Continue to question 59
Continue to question 58
Continue to question 55
Antihypertensive effect less strong than other 
calcium channel blockers: check indication and 
recommend a dihydropyridine instead if used for 
hypertension. Continue to question 56
Monitor blood pressure. Continue to question 58
Antihypertensive effects of 
calcium channel blockers might 
be decreased
Monitor blood pressure and side effects. Continue 
to question 58
Antihypertensive effects of 
calcium channel blockers might 
be increased
Continue to question 58
Contact prescriber: diltiazem and verapamil are 
contra-indicated in these conditions
Monitor cardiac function Increased risk of cardiac toxicity 57. Is the patient also using: 
58. Is the daily dose within the recommended
range? 
59. Is the patient using: -blocker
-blocker
60. Is the daily dose within the recommended
range?
Lipid control 
61. What’s the patient’s lipid profile? 
2.5 mmol/L
A calcium channel blocker
No calcium channel blocker
Amlodipine
Felodipine
Lercanidipine
Nifedipine
Diltiazem
Verapamil
Rifamycins
Phenytoin
Pioglitazone
Carbamazepine
Grapefruit juice
Norfloxacin
Imidazoles (e.g. fluconazole)
None of these
Heart failure NYHA Class I
Bradycardia
Macrolides (e.g. erythromycin)
Digoxin
As e l e c t i v eα
No selective α
Total cholesterol > 4.0 mmol/L
LDL cholesterol >
HDL cholesterol < 1.0 mmol/L
Triglycerides > 1.5 mmol/L
None of the above
Monitor digoxin levels and clinical status Digoxin toxicity might occur
Amlodipine: 2.5 – 10 mg in 1 dose
Felodipine: 5 – 20 mg in 1 dose
Lercanidipine: 10 – 20 mg in 1 dose
Nifedipine: 20 – 80 mg in 2 doses
(controlled release): 20 – 120 mg in 1 dose
Diltiazem: 180 – 360 mg in 1 dose
Verapamil: 120 – 480 mg in 1 dose
Contact prescriber to adjust dose / frequency  if not 
Check medication history: consider 
recommending another antihypertensive agent
Not the preferred agent in the 
hypertension management of 
type 2 diabetes 
Continue to question 61
Prazosin: 12.5 – 25 mg in 2 or 3 doses
Terazosin: 12.5 – 25 mg in 1 dose Contact prescriber to adjust dose / frequency  if not 
A dose change or additional lipid-lowering agent 
might be needed
Patient’s cholesterol levels are 
poorly controlled
Check glycaemic control: high blood glucose 
levels can cause high triglycerides 
Patient’s triglyceride levels are 
poorly controlled
Patient’s lipid levels are well controlled
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12362. Is the patient suffering from:
63. Is the patient using any lipid-lowering
medications?
64. Is the patient using: 
65. Is the patient suffering from:
4
66. Is the daily dose within the recommended
range?
Make sure these disorders are being treated 
adequately  
These might be secondary 
causes of dyslipidaemia
Continue checklist
Check for missing therapy. Continue to question 
77  
Nearly all patients with type 2 
diabetes should be using lipid-
lowering medication(s)
Ask patient about side effects: gastrointestinal 
upset, headache and especially muscle aches (for 
risk of rhabdomyolysis)
Continue to question 70
Carefully monitor liver function, consider 
discontinuing the stating and changing therapy if 
impaired  
Increased risk of hepatoxicity 
Atorvastatin: 10 – 80 mg in 1 dose
Simvastatin: 10 – 80 mg in 1 dose
Fluvastatin: 40 – 80 mg in 1 or 2 doses
Pravastatin: 20 – 80 mg in 1 or 2 doses
Rosuvastatin: 5 – 40 mg in 1 dose
Contact prescriber to adjust dose / frequency  if not 
67. Which statin is the patient using?
68. Is the patient also using: le)
69. Is the patient also using:
70. Is the patient using:
71. Is the patient suffering from:
3
Hypothyroidism
Obstructive liver disease
Nephrotic syndrome
Yes
No
A statin
No statin
Hepatic impairment
Atorvastatin
Simvastatin
Fluvastatin
Pravastatin
Rosuvastatin
Imidazoles (e.g. fluconazo
Macrolides (e.g. erythromycin)
Protease inhibitors
Rifamycins
Carbamazepine
Cyclosporin
Fibrates
Af i b r a t e
No fibrate
Severe renal impairment
Hepatic impairment
4
Continue to question 68 Metabolized through CYP3A4
Continue to question 69
Atorvastatin or simvastatin 
levels may be increased: higher 
risk of adverse effects
Atorvastatin or simvastatin 
levels may be decreased
Monitor the patient’s clinical response
Carefully monitor for clinical symptoms 
Increased risk of myopathy
Ask patient about side effects: dyspepsia and 
abdominal pain
Continue to question 74
Contact prescriber: fibrates  are contra-indicated 
in these conditions
Fenofibrate 145 mg in 1 dose
Gemfibrozil 1200 mg in 2 doses
72. Is the daily dose within the recommended
range?
73. Is the patient also using:
Contact prescriber to adjust dose / frequency  if not 
Increased risk of bleeding  Avoid combination or monitor INR frequently Warfarin
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12374. Is the patient using:
75. Is the daily dose within the recommended
range?
76. Is the patient also using:
Platelet control
77. Is the patient using any anti-platelet
medications?
78. Is the patient using: - dose aspirin (< 150 mg)
-dose aspirin 
Ask patient about side effects: myopathy, 
headache and diarrhea
Continue to question 77
Contact prescriber to adjust dose / frequency  Ezetimibe 10 mg in 1 dose  if not 
Use this combination with caution   Levels of ezetimibe as well as 
cyclosporine might be elevated
Continue checklist
Check for missing therapy. Continue to question 
88 
Nearly all patients with type 2 
diabetes should be using anti-
platelet medication(s)
Ask patient about side effects: gastrointestinal 
irritation and increased bleeding time 
Continue to question 81
79. Is the patient suffering from:
order
3
4
80. Is the daily dose within the recommended
range?
81. Is the patient also using:
82. Is the patient using:
83. Is the patient suffering from:
Ezetimibe
No ezetimibe
Cyclosporin
Yes
No
Low
No low
Active peptic ulceration
Allergy to aspirin or NSAIDs
Ab l e e d i n gd i s
Severe renal impairment
Hepatic impairment
Clopidogrel
Other NSAIDs
Corticosteroids
Clopidogrel
No clopidogrel
An active internal bleeding
Hepatic impairment
84. Is the daily dose within the recommended
range?
Contact prescriber: aspirin is contra-indicated in 
these conditions
Carefully monitor aspirin use Increased risk of bleeding
Aspirin 75 – 150 mg in 1 dose  Contact prescriber to adjust dose / frequency  if not 
Carefully monitor concomitant use Increased risk of bleeding
Carefully monitor concomitant use
Efficacy of aspirin might be 
reduced; increased risk of 
gastrointestinal irritation
Ask patient about side effects: (gastrointestinal) 
bleeding, diarrhea and rash
Continue to question 86
Contact prescriber: clopidogrel is contra-indicated 
in this condition
Carefully monitor clopidogrel use Increased risk of bleeding
Clopidogrel 75 mg in 1 dose  Contact prescriber to adjust dose / frequency  if not 
Carefully monitor concomitant use Increased risk of bleeding 85. Is the patient also using:
86. Is the patient using:
NSAIDs
Dipyridamole
No dipyridamole
87. Is the daily dose within the recommended 
range? 
Adherence
88. Is the patient adherent to his / her
medications?
Yes
No
END OF CHECKLIST
Ask patient about side effects: headache, diarrhea, 
nausea and hypotension 
Continue to question 86
Dipyridamole 400 mg in 2 doses  Contact prescriber to adjust dose / frequency  if not 
Discuss strategies with the patient to try to 
improve adherence  
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